Chris Holland

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

Max S. Topp, Nicola Gökbuget, Anthony S. Stein et al. · The Lancet Oncology · 2014 · 1.3K citations

Medicine, Hematology, Oncology +13

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Paul Nathan, Jessica C. Hassel, Piotr Rutkowski et al. · New England Journal of Medicine · 2021 · 878 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier et al. · Journal of Clinical Oncology · 2014 · 659 citations

Medicine, Hematology, Oncology +15

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

Jessica C. Hassel, Sophie Piperno‐Neumann, Piotr Rutkowski et al. · New England Journal of Medicine · 2023 · 261 citations · Full text

Medicine, Oncology, Pharmacology +17

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Gerhard Zugmaier, Nicola Gökbuget, Matthias Klinger et al. · Blood · 2015 · 161 citations · Full text

Medicine, Immunology, Oncology +16